Kyprolis

Product Description

What is KYPROLIS( Carfilzomib ) for Injection ?

Kyprolis® (carfilzomib) for Injection, a proteasome inhibitor, is approved for the treatment of patients with multiple myeloma who have received at least two prior therapies, including bortezomib and an immunomodulatory agent, and have demonstrated disease progression on or within 60 days of completion of the last therapy.

The U.S. Food and Drug Administration (FDA) approved it on 20 July 2012

What are KYPROLIS safety information ?

ADCETRIS should not be taken alone.

It is not known if ADCETRIS is safe and effective in children under 18 years of age.

How supplied/storage and handling ?

Supplied: KYPROLIS (carfilzomib) for Injection is supplied as an individually cartoned single-use vial containing a dose of 60 mg of carfilzomib as a white to off-white lyophilized cake or powder.  NDC 76075-101-01, 60 mg carfilzomib per vial

Storage and Handling: Unopened vials should be stored refrigerated (2°C to 8°C; 36°F to 46°F). Retain in original package to protect from light.